Stock ABEO ABEONA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Abeona Therapeutics Inc.

Equities

ABEO

US00289Y2063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
7.93 USD +2.19% Intraday chart for Abeona Therapeutics Inc. +7.74% +58.28%
Mar. 18 Sector Update: Health Care Stocks Edge Up Late Monday Afternoon MT
Mar. 18 Sector Update: Health Care Stocks Rise Monday Afternoon MT

Business Summary

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Number of employees: 84

Sales per Business

USD in Million2022Weight2023Weight Delta
Gene and Cell Therapies
100.0 %
1 100.0 % 4 100.0 % +147.52%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 4 100.0 % +147.52%

Managers

Managers TitleAgeSince
Vishwas Seshadri CEO
 Chief Executive Officer 48 21-05-31
Michael Amoroso CHM
 Chairman 46 20-07-08
Joseph Vazzano DFI
 Director of Finance/CFO 40 22-03-13
Amanda Moore CTO
 Chief Tech/Sci/R&D Officer - 20-09-30
Brian Kevany CTO
 Chief Tech/Sci/R&D Officer - 17-12-31
Igor Grachev CTO
 Chief Tech/Sci/R&D Officer 63 21-07-31
Christine Silverstein BRD
 Director/Board Member 41 16-05-02
Greg Gin IRC
 Investor Relations Contact - 20-04-30
Madhav Vasanthavada PRN
 Corporate Officer/Principal - -
Alison Hardgrove HRO
 Human Resources Officer - 22-01-31

Members of the board

Members of the board TitleAgeSince
Mark Alvino BRD
 Director/Board Member 56 06-02-28
Faith Charles BRD
 Director/Board Member 62 21-03-24
Leila Alland BRD
 Director/Board Member 61 21-04-18
Christine Silverstein BRD
 Director/Board Member 41 16-05-02
Michael Amoroso CHM
 Chairman 46 20-07-08
Donald Wuchterl BRD
 Director/Board Member 54 21-04-18
Vishwas Seshadri CEO
 Chief Executive Officer 48 21-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,355,037 25,413,147 ( 92.90 %) 0 92.90 %

Shareholders

NameEquities%Valuation
Adage Capital Partners GP LLC
11.88 %
3,249,994 11.88 % 24 M $
Nantahala Capital Management LLC
8.226 %
2,250,252 8.226 % 16 M $
Millennium Management LLC
5.186 %
1,418,675 5.186 % 10 M $
Vanguard Global Advisers LLC
4.025 %
1,101,131 4.025 % 8 M $
Western Standard LLC
2.954 %
808,112 2.954 % 6 M $
AIGH Capital Management LLC
2.880 %
787,769 2.880 % 6 M $
Point72 Asset Management LP
2.781 %
760,870 2.781 % 6 M $
Ikarian Capital LLC
2.193 %
600,000 2.193 % 4 M $
Vishwas Seshadri
1.931 %
528,260 1.931 % 4 M $
Citigroup Global Markets, Inc. (Investment Management)
1.646 %
450,347 1.646 % 3 M $

Company contact information

Abeona Therapeutics, Inc.

6555 Carnegie Avenue 4th floor

44103, Cleveland

+646 813 4701

http://www.abeonatherapeutics.com
address Abeona Therapeutics Inc.(ABEO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Abeona Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.93 USD
Average target price
21 USD
Spread / Average Target
+164.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ABEONA THERAPEUTICS INC. Stock Abeona Therapeutics Inc.
+58.28% 217M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.78% 41.36B
LONZA GROUP AG Stock Lonza Group AG
+45.43% 41.3B
MODERNA, INC. Stock Moderna, Inc.
+4.01% 39.61B
CELLTRION, INC. Stock Celltrion, Inc.
-15.14% 25.62B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.16% 24.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.08% 18.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.67% 11.82B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+24.76% 11.85B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.01% 11.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ABEO Stock
  4. Company Abeona Therapeutics Inc.